NCT06425198View on ClinicalTrials.gov

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Hepatic ImpairmentHealthy Participants
Interventions
DRUG

BMS-986278

Specified dose on specified days

Trial Locations (4)

32809

Local Institution - 0003, Orlando

33027

Local Institution - 0001, Miami Lakes

33618

Local Institution - 0002, Tampa

78215

Local Institution - 0004, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY